Literature DB >> 11001236

Early termination of antidepressant drug treatment.

M Linden1, H Gothe, R W Dittmann, B Schaaf.   

Abstract

Guidelines for antidepressant drug therapy recommend continuing treatment for several months, even after recovery. Premature termination of medication is viewed as a significant reason for chronicity in depressive disorders. To study the scope and type of this problem, routine treatment cases must be observed in sufficient numbers. In four subsequent drug utilization observation studies, the time course and reasons for early termination (i.e., during the first weeks of fluoxetine treatment for depression) were investigated in (1) 15,601 patients of 4,696 general practitioners; (2) 2,401 patients of all ages treated by 479 neuropsychiatrists from 1990 to 1991; (3) 757 patients of all ages treated by 213 neuropsychiatrists from 1992 to 1993; and (4) in 977 geriatric subjects treated by 216 neuropsychiatrists. In study 1, treatment was terminated during the first 10 weeks in 32.9% of cases; in study 2, in 48.0%; in study C, in 31.2%; and in study D, in 31.0%. When treatment was discontinued because of adverse events, the median of treatment duration was approximately 15 days; in cases of clinical deterioration, 20 days; in cases of poor response, 40 days; and when the reason was good response, the median of treatment duration was approximately 43 days. This is the largest field study on early termination of antidepressant treatment available to date. The consistency of results, which were collected from a large number of patients of different ages and from specialists as well as general practitioners, speaks for the validity and stability of the observed phenomena. The different forms of early treatment termination are discussed and addressed separately because they each have special risks and are differently associated with treatment failure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001236     DOI: 10.1097/00004714-200010000-00005

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  6 in total

Review 1.  Antidepressant treatment in children and adolescents: bridging the gap between efficacy and effectiveness.

Authors:  J M Zito; D J Safer
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

2.  Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.

Authors:  Diane Warden; Madhukar H Trivedi; Stephen R Wisniewski; Benji Kurian; Sidney Zisook; Susan G Kornstein; Edward S Friedman; Sachiko Miyahara; Andrew F Leuchter; Maurizio Fava; A John Rush
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

3.  A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database.

Authors:  M L Murray; C S de Vries; I C K Wong
Journal:  Arch Dis Child       Date:  2004-12       Impact factor: 3.791

4.  MedLink: A mobile intervention to improve medication adherence and processes of care for treatment of depression in general medicine.

Authors:  Marya E Corden; Ellen M Koucky; Christopher Brenner; Hannah L Palac; Adisa Soren; Mark Begale; Bernice Ruo; Susan M Kaiser; Jenna Duffecy; David C Mohr
Journal:  Digit Health       Date:  2016-08-03

5.  Occurrence of Side Effects in Treatment-Resistant Depression: Role of Clinical, Socio-Demographic and Environmental Characteristics.

Authors:  Anna Levy; Wissam El-Hage; Djamila Bennabi; Etienne Allauze; Alexandra Bouvard; Vincent Camus; Philippe Courtet; Jean-Michel Dorey; Bruno Etain; Guillaume Fond; Jean-Baptiste Genty; Jérôme Holtzmann; Mathilde Horn; Marion Leboyer; Pierre-Michel Llorca; Manon Meyrel; Fanny Molière; Anne-Sophie Nguon; Jean Petrucci; Romain Rey; Raphaelle Richieri; Florian Stephan; Guillaume Vaiva; Michel Walter; Emmanuel Haffen; Bruno Aouizerate; Antoine Yrondi
Journal:  Front Psychiatry       Date:  2021-12-06       Impact factor: 4.157

6.  Factors affecting therapeutic compliance: A review from the patient's perspective.

Authors:  Jing Jin; Grant Edward Sklar; Vernon Min Sen Oh; Shu Chuen Li
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.